Israeli biotech Compugen has enlisted John Hopkins University to help assess Compugen’s cancer immunotherapy candidates.  These new treatments aim to counter the ability of tumors to highjack “immune checkpoints”, thereby blocking the immune system’s ability to destroy the tumor. http://www.israel21c.org/news/compugen-teams-with-johns-hopkins-university-on-immune-checkpoints/